TY - JOUR
T1 - Initial Impact and Operational Responses to the COVID-19 Pandemic by American Radiation Oncology Practices
AU - Wakefield, Daniel V.
AU - Sanders, Tim
AU - Wilson, Emily
AU - Hubler, Adam
AU - DeWeese, Theodore
AU - Smith, Benjamin D.
AU - Slotman, Berend J.
AU - Sarria, Gustavo R.
AU - Eichler, Thomas
AU - Schwartz, David L.
N1 - Funding Information:
We thank all the US respondents in the survey, as well as leaders and participants from ESTRO and Latin America for their participation. Disclosures: B.D.S. reports royalty and equity interest in Oncora Medical and prior research funding from Varian Medical Systems. B.J.S. reports a grant from Varian Medical Systems and grants and personal fees from ViewRay Medical Systems. G.R.S. reports grants and personal fees from Carl Zeiss Meditec AG, not related to this work.
Funding Information:
Disclosures: B.D.S. reports royalty and equity interest in Oncora Medical and prior research funding from Varian Medical Systems. B.J.S. reports a grant from Varian Medical Systems and grants and personal fees from ViewRay Medical Systems. G.R.S. reports grants and personal fees from Carl Zeiss Meditec AG, not related to this work.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Purpose: In February 2020, the COVID-19 pandemic reached the United States. The impact of the pandemic on the US radiation oncology field remains unknown. The American Society for Radiation Oncology surveyed US radiation oncology practice leaders to gauge initial impact and immediate operational responses to the pandemic. Methods and Materials: From April 16 to April 30, 2020, the American Society for Radiation Oncology surveyed US radiation oncology practice leaders by email to gauge initial impact and immediate operational responses to the COVID-19 pandemic. Results: Two hundred twenty-two (43%) of 517 leaders responded from community and academic practices (62% and 34%, respectively), hospital-based and free-standing centers (69% and 29%), and metro and rural locations (88% and 12%). Practices reported treating an average of 1086 patients per year in 2019 (range, 0-7900) with an average daily treatment volume of 70 patients (range, 5-400). All practices reported uninterrupted operation. On average, practices were treating 68% of their typical volume (range, 10%-95%), with 92% implementing planned treatment postponement for lower risk patients. An estimated revenue decrease of 20% or more was experienced by 71% of practices. Confirmed COVID-19 patient cases were treated by 39% of practices. Seventy percent experienced staff shortages. Almost all (98%) practices implemented formal operational procedures to protect patients and staff, although personal protective equipment/infection control supply shortages were reported by 78% of practices. Seventy-four percent used telemedicine for virtual follow-up surveillance, and 15% leveraged telemedicine for on-treatment assessment. Conclusions: The clinical and financial impacts of the COVID-19 pandemic on US radiation oncology were deep and broad. Despite reported shortages in personal protective equipment, declines in revenue, and reduced patient volumes, practices adapted quickly by refining standard processes of care, implementing recommended safety measures, and employing telemedicine to facilitate treatment continuity. Patients with higher risk disease experienced uninterrupted access to care. We plan to continue regular surveying across the lifespan of the pandemic to document the geographic and temporal impact of COVID-19 on the field and its patients.
AB - Purpose: In February 2020, the COVID-19 pandemic reached the United States. The impact of the pandemic on the US radiation oncology field remains unknown. The American Society for Radiation Oncology surveyed US radiation oncology practice leaders to gauge initial impact and immediate operational responses to the pandemic. Methods and Materials: From April 16 to April 30, 2020, the American Society for Radiation Oncology surveyed US radiation oncology practice leaders by email to gauge initial impact and immediate operational responses to the COVID-19 pandemic. Results: Two hundred twenty-two (43%) of 517 leaders responded from community and academic practices (62% and 34%, respectively), hospital-based and free-standing centers (69% and 29%), and metro and rural locations (88% and 12%). Practices reported treating an average of 1086 patients per year in 2019 (range, 0-7900) with an average daily treatment volume of 70 patients (range, 5-400). All practices reported uninterrupted operation. On average, practices were treating 68% of their typical volume (range, 10%-95%), with 92% implementing planned treatment postponement for lower risk patients. An estimated revenue decrease of 20% or more was experienced by 71% of practices. Confirmed COVID-19 patient cases were treated by 39% of practices. Seventy percent experienced staff shortages. Almost all (98%) practices implemented formal operational procedures to protect patients and staff, although personal protective equipment/infection control supply shortages were reported by 78% of practices. Seventy-four percent used telemedicine for virtual follow-up surveillance, and 15% leveraged telemedicine for on-treatment assessment. Conclusions: The clinical and financial impacts of the COVID-19 pandemic on US radiation oncology were deep and broad. Despite reported shortages in personal protective equipment, declines in revenue, and reduced patient volumes, practices adapted quickly by refining standard processes of care, implementing recommended safety measures, and employing telemedicine to facilitate treatment continuity. Patients with higher risk disease experienced uninterrupted access to care. We plan to continue regular surveying across the lifespan of the pandemic to document the geographic and temporal impact of COVID-19 on the field and its patients.
UR - http://www.scopus.com/inward/record.url?scp=85090008796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090008796&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2020.06.060
DO - 10.1016/j.ijrobp.2020.06.060
M3 - Editorial
C2 - 32890512
AN - SCOPUS:85090008796
SN - 0360-3016
VL - 108
SP - 356
EP - 361
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -